戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 iated DNA at the same site in the absence of nogalamycin.
2 rase I-mediated DNA cleavage site induced by nogalamycin.
3 pha are cross-resistant to menogaril but not nogalamycin.
4 noK in the biosynthesis of the anthracycline nogalamycin.
5 cycline antibiotics such as daunorubicin and nogalamycin.
6                       The anthracycline drug nogalamycin, a non-covalent intercalator with preference
7              Many DNA binding ligands (e.g., nogalamycin, actinomycin D, terbenzimidazoles, indolocar
8 is of the complete ABCDEF-ring system within nogalamycin, an anthracycline natural product, was studi
9                                              Nogalamycin, an aromatic polyketide displaying high cyto
10       Construction of the DEF-ring system of nogalamycin and menogaril has been achieved with a novel
11                    We found that adriamycin, nogalamycin, and actinomycin D comprise a class of drugs
12                                        Using nogalamycin as a model, we have studied the mechanism of
13                         Substitution of this nogalamycin binding site with a DNA bending sequence (A(
14 T-rich regions are known to be essential for nogalamycin binding.
15        Further, the anthracycline antibiotic nogalamycin binds cleanly to the 5'-TG (5'-CA) site form
16 nerated using the X-ray structure of the DNA-nogalamycin complex.
17                     The structure of the 1:1 nogalamycin:d(ATGCAT)2 complex has been determined in so
18 ng property of nogalamycin, suggest that the nogalamycin-DNA complex may provide a DNA structural ben
19 rprisingly, DNase I footprinting analysis of nogalamycin-DNA complexes has revealed a drug-free regio
20       The complex resembles the structure of nogalamycin-DNA complexes with the drug bound at 5'-TG s
21 in > chromomycin A3, and the specificity was nogalamycin > chromomycin A3 > hedamycin.
22 tion was in the following order: hedamycin > nogalamycin > chromomycin A3, and the specificity was no
23 revent TC formation on the SRE in vitro were nogalamycin > Hoechst 33342 > chromomycin.
24 in NIH3T3 cells, however, were chromomycin > nogalamycin > Hoechst 33342.
25 ities, including ethidium, daunorubicin, and nogalamycin, have been used to probe the flexibility of
26                     Our results suggest that nogalamycin, in contrast to camptothecin, may stimulate
27 ved in two related X-ray structures in which nogalamycin is bound at terminal 5'-TpG sites.
28           Steric occlusion prevents a second nogalamycin molecule from binding at the symmetry-relate
29                                              Nogalamycin monooxygenase (NMO) from Streptomyces nogala
30  reactions of dithranol, a substrate for the nogalamycin monooxygenase (NMO) from Streptomyces nogala
31 ng of the anthracycline antitumor antibiotic nogalamycin (Ng) to these two heptamers stabilizes the d
32                                              Nogalamycin (NOG) is a member of the anthracycline glyco
33                                 By contrast, nogalamycin poisons topoisomerase I but not topoisomeras
34                       The mechanism by which nogalamycin poisons topoisomerase I has been studied by
35 ition of both EGR1 and TBP, the intercalator nogalamycin prevented EGR1 complex formation, resulting
36 ether with the known DNA bending property of nogalamycin, suggest that the nogalamycin-DNA complex ma
37 NA footprinting analyses that the binding of nogalamycin to an upstream site (from position -6 to -3)
38                                              Nogalamycin was most effective when the drug was pre-inc
39 s, respectively, and the intercalating agent nogalamycin, which binds G/C-rich sequences in the major
40      We show that the nogalose sugar ring of nogalamycin, which binds to the minor groove of DNA, pla